ISCT 2024 Annual Meeting
Catalent extends a warm invitation to all attendees to join us at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting held at the stunning Vancouver Convention Centre.
Date: Wednesday, May 29 – Saturday, June 1, 2024
Location: Vancouver Convention Centre West Building, 1055 Canada Place, Vancouver, BC V6C 0C3
Booth: 508
JOIN US!
Complete the form to schedule a meeting with Catalent at ISCT 2024.
WHY SHOULD YOU ATTEND?
This premier gathering brings together the foremost experts and innovators in cell and gene therapy from around the globe, and Catalent is happy to be exhibiting and presenting, with our own Rupa Pike serving as a panelist and Boris Greber & Daniel Terheyden-Keighley delivering a Global Showcase.
SPEAKING ENGAGEMENTS
15 Minute Global Showcase
Title: Toolbox for iPS Cell-Based Therapy
Date: Thursday, May 30, 2024
Time: 12:30 pm – 12:45 pm
Location: Theatre B, Slot: 7B
Description: Explore Catalent’s latest innovations including GMP iPSC lines, enhanced gene editing, new protocols for MSC, cardiac, as well as RPE induction, and a novel feeder-free NK differentiation/expansion platform.
SPEAKERS
Boris Greber
Head of Research and Development, iPSC/CT
Daniel Terheyden-Keighley
Scientist
In addition, Rupa Pike will be a panelist on the following session:
Title: Industrializing Manufacturing & Distribution
Date: Friday, May 31, 2024
Time: 3:45 pm – 4:45 pm
Description: This session will showcase the current state of the industry and will highlight how the leaders in the field are thinking of innovation in terms of NextGen Manufacturing, engineering processes to optimize fixed and operating cost considerations, reducing time in manufacturing and/or QC release, with advances in process & analytical technologies leading to accessibility/availability to such ‘curative’ therapies to patients.
Rupa Pike
Senior Director, Head of Field Scientists and Strategic Alliance, Cell Therapy
Related Topics
ABOUT CATALENT CELL & GENE THERAPY
Catalent Cell & Gene Therapy is an industry-leading technology, development, and manufacturing partner for advanced therapeutics. Its comprehensive cell therapy portfolio includes a wide range of expertise across a variety of cell types including CAR-T, TCR, TILs, NKs, iPSCs, and MSCs. With deep expertise in viral vector development, scale-up and manufacturing for gene therapies and viral vectors, Catalent is a full-service partner for plasmid DNA, adeno-associated viral (AAV), lentiviral and other viral vectors, and oncolytic viruses. An experienced and innovative partner, Catalent Cell & Gene Therapy has a global network of dedicated development, clinical and commercial manufacturing facilities for small- and large-scale programs.
